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Abstract 
 
Human inflammatory breast cancer (IBC) and Canine inflammatory mammary cancer 
(CIMC) are the most aggressive forms of mammary cancer. Current research aims to identify 
new therapeutic targets. Here, we investigated gene expression levels of biomarkers 
associated with the inflammatory microenvironment. 
A total of 32 formalin-fixed paraffin-embedded samples of canine mammary carcinoma 
(CIMC=26; non-CIMC =6) were used and their cDNA subjected to quantitative PCR (qPCR)  
to establish  gene expression levels for mediators commonly implicated in linking 
carcinogenesis with inflammation. Gene expression differences between CIMC and non-
CIMC types were obtained for COX-2 (P=0.004), synuclein gamma (P=0.006), tribbles1 
(P=0.025), VEGF (P=0.017) and CSF1R (P=0.045). Among these biomarkers correlations 
were found, particularly between SNCG and tribbles1 (r=0.512, P=0.001).  
The efficient metastasis of CIMC is intimately linked to components in the tumour 
microenvironment. This study suggests that upregulation and correlation of SNCG and 
tribbles1 deserves to be further explored. 
 
Keywords: inflammation, inflammatory breast cancer, canine inflammatory mammary 
carcinomas 
 
 
 
 
 
 
 
  
Introduction 
 
Inflammatory breast cancer (IBC) in humans and the corresponding canine disease, 
designated as canine inflammatory mammary carcinoma (CIMC), represent the most 
aggressive type of mammary cancer in both species with invariably short survival times after 
diagnosis.1-3 
Inflammatory mammary carcinomas in companion animals were firstly described in 
dogs 4 and more recently in cats.5 This highly metastatic type of breast cancer presents unique 
histopathological features and clinical signs, similar for both humans and canines. In face of 
these resemblances, the possibility of using CIMC as model of study for human IBC has been 
purposed by several authors.6-9 In both species, the histological hallmark of inflammatory 
carcinomas is the formation of tumour emboli in dermal lymphatic vessels resulting in 
profuse oedema, due to the obstruction of lymph drainage.10,11 
During the initiation step of carcinogenesis, malignant transformation is triggered by 
the accumulation of DNA mutations.12 The inflammatory conditions may provide the 
necessary genetic instability to the activation of DNA damage leading to these initiating 
events of carcinogenesis.13,14 Considering human IBC or CIMC as types of cancer with 
chronic inflammation, expression of diverse cytokines and inflammatory mediators has been 
explored in search for an explanation for the severe aggressiveness of the disease. 
Dogs bearing CIMC have been shown to have increased IL-10 (interleukin-10) and IL-8 
(interleukin-8) serum concentrations compared to dogs diagnosed with other malignant or 
benign mammary tumours.15 In human patients with IBC, analysis of a cytokine prolife of 
monocytes from breast draining veins has shown that TNF-α (tumour necrosis factor alpha), 
IL-10 and IL-8 have significantly increased motility and invasion of IBC cancer cell lines in 
vitro.16 These observations contribute to the growing body of evidence suggesting the value 
  
of CIMC as a model for the corresponding human disease,6 and also strengthen the concept of 
tumour-associated macrophages as determinant elements in the establishment of a tumour-
favourable microenvironment.  
For both species, the high aggressiveness and fatality of this disease comparatively to 
other breast cancer types, demands a wider range of therapeutic options and prognostic 
factors to help categorize patients and provide the better treatment. Due to the metastatic 
success of human IBC and CIMC, knowledge obtained for this cancer type could be applied 
to the prevention of other cancer types where an inflammatory microenvironment is present. 
Also, the discovery of new therapeutic targets may provide new opportunities for the 
treatment of this aggressive disease in both humans and canines. 
Expression of COX-2 (cyclooxygenase 2) and VEGF (vascular endothelial growth 
factor) has been shown to have prognostic value for both IBC and CIMC.6,17 Signalling of 
macrophage proliferation and differentiation occurs through the receptor of CSF-1 
(macrophage colony stimulating factor 1) , CSF1R.18 The recruitment of blood monocytes 
into the tumour is governed mainly by the chemokine CCL2 (monocyte chemotactic protein 
1) and its receptor CCR2.19 Overall, the presence of a macrophage infiltrate in breast cancer 
has been shown to correlate with features of malignancy and a worse prognosis.20,21synuclein 
gamma, in its turn, has been investigated for a role in invasion in vitro and metastasis of 
breast cancer in vivo in a mouse model,22 showing also a prognostic value.23 Tribbles1 is 
governed by Snail and Twist, important transcription factors during the EMT (epithelial to 
mesenchymal transition),24 when vimentin is expressed as a mesenchymal marker. 
In this study, it was our aim to characterize the genetic expression of biomarkers known 
to be involved in several aspects of the tumour microenvironment of CIMC: angiogenesis 
(COX-2 and VEGF), macrophage infiltration (CCR2, CSF1R, CCL2), invasion and 
metastasis (synuclein gamma - SNCG) and epithelial to mesenchymal transition (Tribbles1, 
  
vimentin). Simultaneously, by investigating new tumour biomarkers in CIMC, we try to 
identify new therapeutic targets that could be used to increase our knowledge on this disease 
and improve overall survival times of canine patients with CIMC. 
 
Materials and methods 
 
Tumour samples 
From the histopathology archives of INNO Laboratories, (Braga, Portugal) 26 formalin 
fixed paraffin embedded samples of canine inflammatory mammary tumours were obtained. 
These samples had been taken from of dogs by large incisional biopsy (n=26). Animals 
presented to consult with clinical signs of inflammatory mammary carcinoma (oedema, skin 
redness, pain, warmth) and by histopathologic analysis, the characteristic invasion of dermal 
lymphatic vessels by tumour emboli was confirmed. Samples were retrieved between the 
years of 2010 and 2012. Other non-inflammatory mammary tumours, classified histologically 
as tubulopapillary carcinomas (n=6), were obtained to compare against the CIMC tumour 
series. These tumour samples have been partially used in another study by our group, 
currently submitted for publication. 
 
Histopathologic evaluation 
All specimens had been fixed in 10% neutral buffered formalin for 2 to 7 days, and 
after macroscopic analysis, sections representative of the tumour lesions were dehydrated and 
embedded in paraffin. A 3µm thick section was processed for routine haematoxylin and eosin 
(HE) staining for diagnostic purposes. Tumours were independently evaluated by two 
veterinary pathologists (J.P. and I.P.) who then agreed on the established diagnoses, 
according to the criteria defined by World Health Organization (WHO) for the histological 
  
classification of mammary tumours of domestic animals.25 The histopathologic diagnosis 
stated the presence of dermal lymphatic invasion and through investigation of the medical 
records, clinical signs of CIMC were confirmed for a definite diagnosis. The 
clinicopathological characteristics observed included: ulceration, necrosis, lymph node 
metastasis, vascular mimicry, mitotic grade, tubular differentiation grade, nuclear grade and 
histological grade of malignancy. Vascular mimicry was determined by the presence of 
endothelial-like cells, following previously published criteria.26 The number of mitosis was 
counted in 10 high-power fields and classified in 3 grades according to the recommended 
guidelines.11 Tubular differentiation, nuclear grade and histological grade of malignancy were 
also evaluated according to the recent recommendations for CMT grading. 11 The anonymity 
of the patients was maintained throughout this study. Client consent for use of patient samples 
was obtained for all the cases.  
 
RNA extraction and cDNA synthesis 
The extraction of RNA from formalin-fixed paraffin-embedded tumour samples was 
carried out using PureLink FFPE Total RNA Isolation Kit (K1560-02, Invitrogen, Carslbad, 
CA, USA), according to the manufacturers recommendations. For this study, 26 formalin 
fixed paraffin embedded tumour samples of CIMC and 6 tubulopapillary carcinomas were 
analysed. Briefly, five 10µm tissue sections were dewaxed and lysed with proteinase K. The 
lysate was purified through binding and washing steps. Finally, the eluted RNA was digested 
with DNase I (Invitrogen, Carslbad, CA, USA) eliminate genomic DNA contamination. The 
RNA quantity and 260/280 ratios were verified on the spectrophotometer Nanodrop 1000 
(ThermoScientific, Waltham, MA, USA) and integrity was checked by examining the 
presence of mRNA subunits after running a 5µL sample in a 2% agarose gel. The presence of 
clear bands, without a vertical smear indicated good integrity RNA.  
  
Since most samples did not have mRNA integrity of the required quality, cDNA 
synthesis was carried out by an alternative method employing Single Primer Isothermal 
Amplification (SPIA) technology as recommended by the manufacturer of Ovation FFPE 
WTA System (3403, Nugen, Leek, Netherlands). The complete process of cDNA synthesis 
by SPIA consists in the generation of two strands of cDNA in two separate steps which are 
amplified by SPIA at the end of the process. Firstly, RNA demodification was carried out to 
eliminate the formation of secondary structure RNA, followed by the primer annealing and 
then the synthesis of hybrid cDNA strands.  
For the purification of the cDNA obtained, the Agencourt RNAClean XP purification 
beads, supplied with the Ovation FFPE WTA system were applied and the purified DNA used 
in the final step of SPIA amplification. A step of cDNA purification followed using the 
Qiagen QIAquick PCR Purification Kit (28104, Qiagen, Limburg, Netherlands).  
The quality of cDNA was verified as previously described, by performing amplification 
of reference genes (HPRT, GAPDH or RSP19) by standard polymerase chain reaction, using 
a Taq polymerase, before processing the samples for qPCR. 
 
Quantitative Real Time PCR (qPCR) 
Sequences of canine mRNA for the target genes were obtained from the Ensembl 
website (www.ensembl.org/Canis_familiaris). Primers were designed using PrimerPlus online 
software (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/) applying the 
optimal qPCR settings, and checked for the presence of hairpins, primer dimer formation at 
low entropy with the Oligo DT analyzer web tool (https://www.idtdna.com/calc/analyzer). 
To assure the amplification of coding regions and not any remainder genomic cDNA, 
the location of at least one of the primers spanning exon-exon junctions was confirmed by 
  
using the online tool Primer-Blast (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The 
primer sequences and relevant parameters are listed on table 1. 
In agreement with recommendations for good practices in qPCR experiments,27 the 
geometric mean of RNA gene expression of three reference genes (GAPDH, RPL32, RSP19) 
was used to determine the relative expression of target genes. 
The concentration of the primers used was optimized beforehand using serial dilutions 
of cDNA synthesized from mRNA obtained from REM 134 cells. For each sample three 
technical replicates were run and dissociation curves analysed individually to rule out the 
formation of non-specific PCR products, such as primer dimers and background 
amplification. The presence of a single peak at the known product melting temperature and 
the absence of any primer- dimers that might have generated a peak at a lower temperature 
was the criteria used to assess the purity of the PCR product.28 Standard curves were 
produced from serial dilutions of samples to evaluate the PCR efficiency.  
For the qPCR reaction, primers were diluted at concentrations of 100-300nM, according 
to previous optimization results, and cDNA was diluted 1:10. The components of a master 
mix were set according to the instructions of the manufacturers of SYBR green UDG (11733-
046, Invitrogen, Carslbad, CA, USA). The qPCR thermal cycler (Agilent, MxPro 3005, USA) 
was programmed for : UDG incubation at 500C for 2 mins, Taq activation at 95ºC for 2 min; 
45 cycles of 95ºC for 15 seconds, 60ºC for 30 seconds; and finally 95ºC for 1 min, 60ºC for 
30seconds, 95ºC for 15 seconds and 25ºC for 30seconds. The extended 45 cycle program was 
set to determine low levels of transcript levels, registered from Ct=21 up till Ct=38. Data was 
analysed in the MxPro software (Agilent, USA). According to Schmittgen and Livak 
(2008),29the target gene expression relative to the reference gene was calculated by applying 
the following formula to the mean Ct values for each sample: 2-ΔCt=2-Ct (ref gene) - Ct(target gene) 
where Ct designates the cycle threshold at which the fluorescent light overcomes the 
  
background noise and the result is expressed in arbitrary units. The geometric mean of the Ct 
values for the reference gene was considered.  
 
Statistical analysis 
To compare means of two groups with non-parametric distributions, Wilcoxon rank-
sum test was used. For the analysis of correlations between non-parametric distribution 
groups, a Kendal tau B statistical test was used. Analysis of associations with 
clinicopathological variables was performed by using Chi-Square Pearson statistical test. The 
statistical analysis was performed using the software SPSS v.17.0 (Statistical Package for the 
Social Sciences, IBM). To divide values of relative gene expression into low and high, the cut 
off value was applied by the median values of RGE for each group. The statistical 
significance value was considered to be P<0.05. 
 
Results 
 
Tumour samples 
The tumours used in this study were obtained from a population of dogs of varied 
breeds (Table 2). In the group of inflammatory carcinomas, mongrels are the largest group 
represented (38.5%). The mean age of the animals from both groups was comparable (10.8 
years old in both groups). The information on the status of lymph node metastasis was not 
available for 53.9% (n=14) of the cases of inflammatory carcinomas and 33.6% (n=2) of the 
non-inflammatory carcinomas group. All the tumour samples of inflammatory carcinomas 
had arisen as primary tumours. The histopathologic analysis of malignancy grade confirmed 
all these tumours had high histopathologic grade of malignancy (grade 3).  
 
  
Relative gene expression of canine mammary Inflammatory versus non-inflammatory 
carcinomas 
In the group of inflammatory carcinomas, relative gene expression expressed as mean±SEM 
was 0.566±0.018 for COX-2, 0.050±0.016 for VEGF, 0.516±0.321 for tribbles1, 0.138±0.049 
for synuclein gamma, 0.0168±0.009 for CCR2, 0.010±0.003 for CSF1R, 1.845±0.578 for 
vimentin and 40.136±9.517 for CCL2. In the tubulopapillary carcinomas group, expression 
for VEGF and CSF1R was positive in only one of the six cases, expression for COX-2, 
tribbles1, SNCG and CCR2 was negative in all cases, expression 17.967±17.521 for 
vimentin, and 22.465±4.727 for CCL2. 
Relative gene expression (RGE) of COX-2, VEGF-A, SNCG, tribbles 1 and CSF1R 
was higher in inflammatory than in non-inflammatory carcinomas and these differences are 
statistically significant (Figure 1). The differences observed on the RGE values for the other 
biomarkers (CCL2, CCR2 and vimentin) were considered non-significant.  
Regarding correlations between the RGE of biomarkers studied within the group of 
inflammatory carcinomas (Table 3), it is noteworthy a moderate and positive correlation 
between tribbles 1 and synuclein gamma (r=0.512, P=0.001), which might indicate co-
expression in inflammatory carcinomas and suggests an interaction between the two proteins. 
Other weaker positive and statistically significant correlations were obtained between the 
RGE of VEGF-A and tribbles (r=0.396, P=0.008), VEGF-A and COX-2 (r=0.326, P=0.024), 
VEGF-A and SNCG (r=0.314, P=0.031) and CSF1R and tribbles 1 (r=0.310, P=0.042). A 
tendency was observed for a correlation between COX-2 and tribbles 1 (r=0.296, P=0.051) 
with borderline values of statistical significance. 
 
Association between RGE grade and clinicopathological variables 
Within the group of canine inflammatory carcinomas (N=26), the presence of 
associations with the clinicopathological variables studied and the relative gene expression 
  
grade of COX-2, VEGF, tribbles1, SNCG, CCR2, CSF1R, vimentin and CCL2 was analysed 
by Pearson Chi-Square test. 
Between CCR2 relative gene expression grade and the mitotic grade, a statistically 
significant association was observed (P=0.005). Most of the tumours classified with mitotic 
grade 3 (11/13) had high grade CCR2 relative gene expression and conversely, in the majority 
of tumours presenting mitotic grade 2 (moderate) a low grade of CCR2 relative gene 
expression was obtained. For the other biomarkers studied (CSF1R, COX-2, VEGF, CCL2, 
tribbles1, vimentin and SNCG) no statistically significant associations were obtained with 
clinicopathological variables in this study. 
 
Discussion 
 
In this retrospective study, a comparative approach was used to investigate the 
expression of genes that might serve as new biomarkers for canine mammary tumours, and in 
particular, inflammatory carcinomas. One of the main limitations of this study was the 
reduced tumour series size, including only 6 control samples, and limited biological material 
preserved in formalin and embedded in paraffin which we used to extract RNA. The 
reliability of the mRNA extracted from FFPE tissues has been corroborated by other authors 
30-32 and was here verified by previous amplification of reference genes. To our best 
knowledge, the determination of gene expression levels of tribbles 1, CSF1R, CCL2, CCR2, 
synuclein gamma and vimentin constitutes a novelty in dog mammary tumours and therefore 
in inflammatory carcinomas. 
COX-2 is an enzyme converting arachidonic acid into different prostaglandins that 
serves as an important inflammatory mediator.33 The role of COX-2 in breast cancer 
carcinogenesis of both humans and dogs has been studied for its association with formation of 
  
metastasis and angiogenesis 34-36 and a worse prognosis.37 In our results COX-2 
overexpression was verified in CIMC comparatively to non-CIMC tumours, contrary to 
results of COX-2 mRNA expression obtained by comparing a set of IBC with non-IBC 
samples. 38 By ELISA, COX-2 expression has been investigated in tissue homogenates of 
CIMC,7 and higher levels of this enzyme were found relatively to malignant canine mammary 
tumours. In this study we also found a positive correlation between COX-2 and VEGF 
expression, which is in agreement with previous studies in humans 34 and dogs.35 
Vascular endothelial growth factor (VEGF) is a biomarker of angiogenesis associated 
with poor outcome in IBC patients  and overexpressed in  CIMC relatively to non-CIMC 
tumours, as confirmed in our results. 39,40 Also, statistically significant correlations were 
obtained between VEGF and tribbles1 and between VEGF and synuclein gamma, both 
unreported until now in canine mammary tumours. However, since these are weak 
correlations, a study comprising an enlarged population would be necessary to achieve firm 
conclusions on these correlations. 
Tribbles 1 is a gene of the pseudokinase family which has been identified as a myeloid 
oncogene involved in acute myeloid leukaemia,41 although its role as a tumour suppressor 
gene has also been described for the same disease.42 Tribbles 1 is an intervenient the 
regulation of mitosis and cell movements during morphogenesis, controlled by Snail and 
Twist, both involved in epithelial to mesenchymal transition (EMT).24 However, this is not 
the preferred pathway for migration and metastasis in IBC, since downregulation of TGFβ 43 
and a predominance of E-cadherin has been shown in these cases.  
In our results, both tribbles 1 and synuclein gamma appear upregulated in CIMC cases 
and present a statistically significant correlation between them, although its meaning requires 
mechanistic studies to be fully understood. Although it is not likely that synuclein gamma and 
tribbles 1 are cooperating in the EMT process in IBC, both have been studied for the 
  
participation in steps of carcinogenesis. Tribbles 1 expression is not well studied in breast 
cancer yet, but it has been reported to be involved in a breast carcinogenesis mechanism by 
ephrin receptor B6 silencing, as a target of several miRNAs.44 Tribbles 1 has also been 
described to be an independent predictor of prognosis in ovarian cancer in a study of primary 
tumour cultures derived from ascitic fluids.45 Tribbles 1 is recognized as an essential factor 
for prostate carcinoma growth and survival in 3D culture environments, overexpressed in 
clinical samples of prostatic cancer.46 
Synuclein gamma, also designated breast cancer specific gene 1, is a biomarker of poor 
prognosis in triple negative human breast cancer,23 a characteristic of 30-40% of IBC cases. 1 
Synuclein gamma is expressed in neoplastic mammary gland, but not in normal epithelial 
mammary glandular cells.47	In vitro overexpression of synuclein gamma in the breast cancer 
cell line MDA-MBA-435 caused increased cell motility and invasiveness, which was 
confirmed in vivo, by injecting these cells in the mammary fat pads of nude mice, producing 
enhanced metastasis to the lymph nodes and increased tumour cell growth.22 Later on, the 
involvement of synuclein gamma with ERK and Rho GTPases signalling was suggested to be 
responsible for the increased motility and migration observed in breast cancer cell lines in 
vitro.48 In MDA-MB-231 mammary cancer cells, targeting synuclein gamma with siRNA has 
been shown to reduce proliferation and migration dowregulating phosphorylation of ERK and 
AKT, and also induce apoptosis by cell cycle arrest.49 Moreover, in a colon cancer cell line it 
has been demonstrated that induced synuclein gamma overexpression increased cell 
migration, invasion and adhesion to endothelial cells.50 The overexpression of synuclein 
gamma we observed in CIMC could be related with the prominent role of cell migration and 
invasion in this tumour type.	 
Increased RGE of CSF1R was observed in CIMC, similarly to a study of IBC analysing 
NF-κB related genes where CSF1R was found to be upregulated relatively to non-IBC 
  
tumours.51 A statistically significant correlation is also observed between tribbles1 and 
CSF1R relative gene expression, which could reflect tribbles1 involvement in macrophage 
migration 52 which is also partly governed by CSF-1 signalling.18 
Overall, relative gene expression of COX-2, VEGF, tribbles1, SNCG and CSF1R was 
found to be increased in CIMC cases relatively to non-CIMC, which could be implicated in 
the pathogenesis of this disease, but could not be associated with prognosis nor metastasis due 
to limited population and follow up data. 
Relatively to the associations found between CCR2 relative gene expression and the 
mitotic grade (P=0.005), no comparable reports have been found in the literature. However, 
experiments performed in a prostate carcinoma cell line indicated that inhibition of CCR2 has 
caused decreased proliferation and augmented apoptosis,53 which relates to our results. 
Due to the fact that all CIMC tumours had high histological grade of malignancy (grade 
3) no significant associations were established with this clinicopathological variable. 
Surprisingly, in our results no associations with clinicopathological variables were 
observed for COX-2 relative gene expression in CIMC, in agreement with observations for 
other malignant CMT,35 but opposed to what has been verified in other reports 7,54,55 with 
observation of associations to tumour size and histological grade of malignancy.  
Also for VEGF relative gene expression, no association with clinicopathological 
variables was registered here in agreement with some authors,35,56 but contrary to other 
reports.57 These disparate results from a comparative aspect demonstrate the need to continue 
investigating this neoplasia at clinical and molecular levels to better understand its 
pathophysiology.  
 
Conclusions 
  
With this work we aimed to contribute to the study of the tumour microenvironment of 
canine inflammatory mammary carcinomas. To the best of our knowledge this is the first 
report of elevated gene expression levels of synuclein gamma, tribbles 1 and CSF1R in CIMC 
versus other malignant canine mammary tumours. Moreover, significant correlations between 
these markers were found, in particular between synuclein gamma and tribbles 1, which 
might have a role in the aggressive behaviour of CIMC and possibly also in IBC. In IBC the 
role of tribbles1 and synuclein gamma expression has not been evaluated yet, and the 
possibility for their implication in the pathogenesis of this disease will require further 
research. The discovery of novel tumour biomarkers allows an enhanced knowledge on the 
biological behaviour of these aggressive mammary tumour type and suggests potential 
therapeutic targets.  
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Table 1 - Sequence and characteristics of qPCR primers used in this study. 
  
qPCR 
primers 
Sense Sequence 5'-3' Lenght 
(bp) 
GC 
(%) 
Melting 
temperature 
(°C) 
COX-2 
Forward TATCAGGTAATTGATGGAGAGGTG 24 41.67 57.57 
Reverse CAGCAAACTGCAGGTGTTCA 20 50.00 59.26 
CCL2 
Forward TAAAAGAGTCACCAGCAGCAA 21 42.90 54.50 
Reverse TTTAGGACGGTCTTGAAGATCA 21 40.90 53.40 
CCR2 
Forward TCCTTCTCACCATCCCATTC 20 50.00 56.6 
Reverse AGAAGGTCCCGCCAAAATAC 20 50.00 57.88 
CSF1R 
Forward AACAAGACCTGGACAAAGAGGA 22 45.45 59.22 
Reverse TTCTTGGATGCAAGGAAGG 19 47.37 55.05 
Synuclein 
gamma 
Forward GTGGTCACCAGCATCAACAC 20 55.00 59.41 
Reverse GTTGTTCTAGGTCCTCCTTTCG 22 50.00 58.41 
Tribbles 
Forward CATCGCCGACTACCTGCT 18 61.11 59.19 
Reverse TGTTTAATAGGAAACACCTTGCAG 24 37.5 57.67 
VEGFA 
Forward CGAAGTGGTGAAGTTCATGG 20 50.00 56.74 
Reverse GCAGGATGGCTTGAAGATGT 20 50.00 58.24 
Vimentin 
Forward CGGGAGAAGTTGCAAGAGGA 20 55.00 59.68 
Reverse TCCACTTTCCGCTCAAGGTC 20 55.00 59.97 
GAPDH 
Forward GCCTGGAGAAAGCTGCCAAA 20 55.00 61.18 
Reverse CGTCGAAGGTGGAAGAGTGG 20 60.00 60.39 
RPL32 
Forward CATCGATCGCTGGGCATCAT 20 55.00 60.67 
Reverse CTGGTGCCGGATGAACTTCT 20 55.00 60.04 
RSP19 
Forward CCTTCCTCAAAAAGTCTGGG 20 50.00 55.9 
Reverse GTTCTCATCGTAGGGAGCAAG 21 52.38 58.2 
Table 2 - Characteristics of the population studied 
 Breed Age LN metastasis Primary 
CIMC 
  n %    n; % % 
Inflammatory 
carcinomas 
(n=26) 
Mongrel 10 38.5 Mean 10.8 Present 9; 34.6 100 
Poodle 2 7.7 Minimum 6 Absent 3; 11.5  
Cocker 
spaniel 
4 15.4 Maximum 17 Unknown 14; 53.9  
Labrador 
Retriever 
1 3.9 ≤10 years 
old 
n=12; 
46% 
   
Golden 
retriever 
2 7.7 >10 years 
old 
n=14; 
54% 
   
Boxer 3 11.5      
Bichon Frisé 1 3.9      
Pekingese 1 3.9      
German 
Shepherd 
1 3.9      
Great Dane 1 3.9      
         
Non-
inflammatory 
carcinomas 
(n=6) 
Mongrel 1 16.6 Mean 10.8 Present 3; 50  
Husky 1 16.6 Minimum 6 Absent 1; 16.7  
Setter 
Spaniel 
1 16.6 Maximum 16 Unknown 2; 33.3  
Boxer 1 16.6 ≤10 years 
old 
n=3; 
50% 
   
Poodle 1 16.6 >10 years 
old 
n=3; 
50% 
   
Pekingese 1 16.6      
LN - lymph node; CIMC - inflammatory carcinoma 
 
Table 3: Matrix of correlations for the biomarkers studied, obtained by the Kendall's tau b statistical test 
 
Kendall’s tau b 
n=26 VEGF Tribbles1 SNCG CCR2 CSF1R Vimentin CCL2 
COX-2 r=0.326 P=0.024 
r=0.296 
P=0.051 
r=0.240 
P=0.103 
r=0.007 
P=0.962 
r=0.070 
P=0.634 
r=0.070 
P=0.624 
r=-0.127 
P=0.373 
VEGF _ r=0.396 P=0.008 
r=0.314 
P=0.031 
r=0.233 
P=0.123 
r=0.160 
P=0.270 
r=0.134 
P=0.341 
r=0.097 
P=0.493 
Tribbles1 _ _ r=0.512 P=0.001 
r=0.071 
P=0.654 
r=0.310 
P=0.042 
r=0.279 
P=0.590 
r=0.100 
P=0.500 
SNCG _ _ _ r=-0.033 P=0.829 
r=0.253 
P=0.088 
r=0.119 
P=0.407 
r=-0.087 
P=0.545 
CCR2 _ _ _ _ r=0.055 P=0.719 
r=0.124 
P=0.408 
r=-0.081 
P=0.587 
CSF1R _ _ _ :_ _ r=0.177 P=0.218 
r=-0.048 
P=0.737 
Vimentin _ _ _ _ _ _ r=0.163 P=0.243 
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